BioVaxys Technology Corp. and Procare Health Iberia announced that they have finalized and executed the United States Distribution Agreement for Papilocare® and Oral Immunocaps©. Following the binding Term Sheet executed by the two companies in early October 2022, the Distribution Agreement finalized all remaining aspects of the transaction.  Developed by Procare Health, Papilocare® is the world's first and only patented vaginal gel product with clinical evidence to prevent and treat HPV-dependent cervical lesions.  Immunocaps®, which can be used on its own or together with Papilocare®, is an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions.  BioVaxys will immediately begin pursuit of regulatory approval for Papilocare® with the US Food and Drug Administration ("FDA") and anticipates US registration as a Class II medical device.  As Immunocaps® is an OTC supplement, BioVaxys anticipates that regulatory approval will not be required, allowing the rapid build out of sales channels and revenue generation from the product.  BioVaxys plans to begin stocking and distributing Immunocaps© in early 2023.